Molly Li, MBBS

Cecilia Brown

DocwireNews

Molly Li, MBBS, of the Chinese University of Hong Kong, discusses the abstract on the CITADEL trial-in-progress presented at the European Society of Clinical Oncology (ESMO) 2024 Congress.The CITADEL trial, which is evaluating combining immunotherapy with Trop2 antibody-drug conjugates in early-stage non-small cell lung cancer (NSCLC), is an investigator-initiated, open-label, single arm, multicenter phase II study investigating the efficacy of perioperative pembrolizumab plus sacituzumab govitecan in patients with resectable stage II-III NSCLC without EGFR/ALK alterations.&ldquo;This study is currently actively enrolling, and we feel that the enrollment will continue through around 2025 and will end at around the end of next year, so looking forward to the enrollment, as well as the results so far,&rdquo; Dr. Li said.Eligible patients will receive four cycles of neoadjuvant pembrolizumab 200 mg every three weeks and sacituzumab govitecan 10 mg/kg on days one and eight every three weeks. Patients will undergo surgical resection 4 to 8 weeks after the fourth cycle of study treatment. The primary endpoint of the study is the pathological complete response rate.&ldquo;We hypothesize that this perioperative pembrolizumab plus sacituzumab govitecan will offer a better pathological complete response rate compared to the current standard of care, perioperative pembrolizumab plus chemotherapy,&rdquo; Dr. Li said.

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Hatem Soliman, MD

Using Dendritic Cell Vaccines to Boost Neoadjuvant Therapy in HER2+ Breast Cancer

HER2 Breast Cancer

Kathleen Liu, MD

Joel M. Topf, MD, FACP

AKI Approaches and ASN Kidney Health Guidance

NKF Spring Clinical Meetings 2025

Latest News

CITADEL Trial-in-Progress Presented at ESMO 2024

ESMO 2024: Focus on Lung Cancer

Molly Li, MBBS, of the Chinese University of Hong Kong, discusses the abstract on the CITADEL trial-in-progress at the European Society of Clinical Oncology (ESMO) 2024 Congress.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe